Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Change in Accured Expenses (2016 - 2025)

Nephros (NEPH) has 16 years of Change in Accured Expenses data on record, last reported at $380000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 439.29% year-over-year to $380000.0; the TTM value through Sep 2025 reached $901000.0, up 331.62%, while the annual FY2024 figure was -$226000.0, 144.66% down from the prior year.
  • Change in Accured Expenses reached $380000.0 in Q3 2025 per NEPH's latest filing, up from $168000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $380000.0 in Q3 2025 and bottomed at -$380000.0 in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $55842.1, with a median of $98000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: crashed 487.76% in 2024, then soared 663.64% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at -$128000.0 in 2021, then surged by 118.75% to $24000.0 in 2022, then surged by 237.5% to $81000.0 in 2023, then skyrocketed by 201.23% to $244000.0 in 2024, then surged by 55.74% to $380000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $380000.0 in Q3 2025, $168000.0 in Q2 2025, and $109000.0 in Q1 2025.